Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations

This article was originally published in The Pink Sheet Daily

Executive Summary

While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.

Related Content

Deal Watch: After Novartis Deal, GSK Increases Vaccine Emphasis With GlycoVaxyn Buyout
Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate
Mesoblast Advances Stem-Cell Drugs As Catalysts Approach
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon
European Generics Need To Climb Into Niches, Huddle Together For Growth
ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
Teva's Growth Story
Teva Is Eager to Expand in Specialty Pharma
Teva Is Eager to Expand in Specialty Pharma





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts